The dual pathway inhibitor rigosertib is effective in direct-patient tumor xenografts of head and neck squamous cell carcinomas

The dual pathway inhibitor rigosertib inhibits phosphoinositide 3-kinase (PI3K) pathway activation as well as polo-like kinase 1 (PLK1) activity across a broad spectrum of cancer cell lines. The importance of PIK3CA alterations in head and neck squamous cell cancer (HNSCC) has raised interest in exp...

Full description

Saved in:
Bibliographic Details
Main Authors: Anderson, Ryan T., Keysar, Stephen B., Bowles, Daniel W., Glogowska, Magdalena J., Astling, David P., Morton, J. Jason, Le, Phuong, Umpierrez, Adrian, Eagles-Soukup, Justin, Gan, Gregory N., Vogler, Brian W., Sehrt, Daniel, Takimoto, Sarah M., Aisner, Dara L., Wilhelm, Francois, Frederick, Barbara A., Varella-Garcia, Marileila, Tan, Aik-Choon, Jimeno, Antonio
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3796006/
https://ncbi.nlm.nih.gov/pubmed/23873848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-13-0206
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items